Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity

Death receptor agonist therapies have exhibited limited clinical benefit to date. Investigations into why Apo2L/TRAIL and AMG 655 preclinical data were not predictive of clinical response revealed that coadministration of Apo2L/TRAIL with AMG 655 leads to increased antitumor activity in vitro and in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer cell 2014-08, Vol.26 (2), p.177-189
Hauptverfasser:	Graves, Jonathan D., Kordich, Jennifer J., Huang, Tzu-Hsuan, Piasecki, Julia, Bush, Tammy L., Sullivan, Timothy, Foltz, Ian N., Chang, Wesley, Douangpanya, Heather, Dang, Thu, O’Neill, Jason W., Mallari, Rommel, Zhao, Xiaoning, Branstetter, Daniel G., Rossi, John M., Long, Alexander M., Huang, Xin, Holland, Pamela M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - chemistry Antibodies, Monoclonal - pharmacology Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Cell Line, Tumor Cell Survival Crystallography, X-Ray Drug Resistance, Neoplasm Drug Synergism Humans Mice Models, Molecular Protein Multimerization Protein Structure, Quaternary Receptors, TNF-Related Apoptosis-Inducing Ligand - antagonists & inhibitors Receptors, TNF-Related Apoptosis-Inducing Ligand - chemistry Receptors, TNF-Related Apoptosis-Inducing Ligand - metabolism Signal Transduction TNF-Related Apoptosis-Inducing Ligand - chemistry TNF-Related Apoptosis-Inducing Ligand - pharmacology Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!